Cargando…
Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer
BACKGROUND: The aim of this study was to explore the short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer (ER). METHODS: Eighty-eight patients with ER cancer and 82 healthy controls who had completed a full course of inac...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637626/ https://www.ncbi.nlm.nih.gov/pubmed/36353624 http://dx.doi.org/10.3389/fimmu.2022.1028246 |
_version_ | 1784825228553093120 |
---|---|
author | Song, Rui Liu, Li Pan, Qingbo Liu, Jin Tan, Jiahe Deng, Juan Deng, Qin Lin, Zijin Chen, Min Peng, Mingli Ren, Hong Ming, Jia |
author_facet | Song, Rui Liu, Li Pan, Qingbo Liu, Jin Tan, Jiahe Deng, Juan Deng, Qin Lin, Zijin Chen, Min Peng, Mingli Ren, Hong Ming, Jia |
author_sort | Song, Rui |
collection | PubMed |
description | BACKGROUND: The aim of this study was to explore the short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer (ER). METHODS: Eighty-eight patients with ER cancer and 82 healthy controls who had completed a full course of inactivated or peptide-based SARS-CoV-2 vaccines were recruited. Adverse events (AEs) were recorded. Responses to receptor-binding domain IgG antibody (anti-RBD-IgG), neutralizing antibodies (NAbs) and RBD+ memory B cells (MBCs) were evaluated. RESULTS: Approximately 26.14% (23/88) of patients with ER cancer reported AEs within 7 days, which was comparable to that reported by healthy controls (24.39%, 20/82). Both the overall seroprevalence of anti-RBD-IgG and NAbs was obviously lower in the cancer group (70.45% vs. 86.59%, P < 0.05; 69.32% vs. 82.93%, P < 0.05, respectively). Anti-RBD-IgG and NAbs titers exhibited similar results, and dropped gradually over time. Patients with ongoing treatment had an attenuated immune response, especially in patients receiving active chemotherapy. The frequency of overall RBD+ MBCs was similar between the two groups, but the percentage of active MBCs was remarkably reduced in patients with ER cancer. Unlike antibody titers, MBCs responses were relatively constant over time. CONCLUSION: Inactivated and peptide-based COVID-19 vaccines were well tolerated, but with lower immunogenicity for ER cancer patients. More intensive antibody monitoring and timely booster immunization is recommended for patients with ER cancer presenting disordered subpopulations of RBD+ MBCs. |
format | Online Article Text |
id | pubmed-9637626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96376262022-11-08 Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer Song, Rui Liu, Li Pan, Qingbo Liu, Jin Tan, Jiahe Deng, Juan Deng, Qin Lin, Zijin Chen, Min Peng, Mingli Ren, Hong Ming, Jia Front Immunol Immunology BACKGROUND: The aim of this study was to explore the short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer (ER). METHODS: Eighty-eight patients with ER cancer and 82 healthy controls who had completed a full course of inactivated or peptide-based SARS-CoV-2 vaccines were recruited. Adverse events (AEs) were recorded. Responses to receptor-binding domain IgG antibody (anti-RBD-IgG), neutralizing antibodies (NAbs) and RBD+ memory B cells (MBCs) were evaluated. RESULTS: Approximately 26.14% (23/88) of patients with ER cancer reported AEs within 7 days, which was comparable to that reported by healthy controls (24.39%, 20/82). Both the overall seroprevalence of anti-RBD-IgG and NAbs was obviously lower in the cancer group (70.45% vs. 86.59%, P < 0.05; 69.32% vs. 82.93%, P < 0.05, respectively). Anti-RBD-IgG and NAbs titers exhibited similar results, and dropped gradually over time. Patients with ongoing treatment had an attenuated immune response, especially in patients receiving active chemotherapy. The frequency of overall RBD+ MBCs was similar between the two groups, but the percentage of active MBCs was remarkably reduced in patients with ER cancer. Unlike antibody titers, MBCs responses were relatively constant over time. CONCLUSION: Inactivated and peptide-based COVID-19 vaccines were well tolerated, but with lower immunogenicity for ER cancer patients. More intensive antibody monitoring and timely booster immunization is recommended for patients with ER cancer presenting disordered subpopulations of RBD+ MBCs. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9637626/ /pubmed/36353624 http://dx.doi.org/10.3389/fimmu.2022.1028246 Text en Copyright © 2022 Song, Liu, Pan, Liu, Tan, Deng, Deng, Lin, Chen, Peng, Ren and Ming https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Song, Rui Liu, Li Pan, Qingbo Liu, Jin Tan, Jiahe Deng, Juan Deng, Qin Lin, Zijin Chen, Min Peng, Mingli Ren, Hong Ming, Jia Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer |
title | Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer |
title_full | Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer |
title_fullStr | Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer |
title_full_unstemmed | Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer |
title_short | Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer |
title_sort | short-term safety and immunogenicity of inactivated and peptide-based sars-cov-2 vaccines in patients with endocrine-related cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637626/ https://www.ncbi.nlm.nih.gov/pubmed/36353624 http://dx.doi.org/10.3389/fimmu.2022.1028246 |
work_keys_str_mv | AT songrui shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT liuli shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT panqingbo shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT liujin shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT tanjiahe shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT dengjuan shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT dengqin shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT linzijin shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT chenmin shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT pengmingli shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT renhong shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer AT mingjia shorttermsafetyandimmunogenicityofinactivatedandpeptidebasedsarscov2vaccinesinpatientswithendocrinerelatedcancer |